Vapocoolant Spray to Reduce Pain With Nexplanon Insertion
Part of paid clinical trials in Honolulu, Hawaii.
- Sponsor
- Queen's Medical Center
- Study ID
- NCT06933381
- Status
- Recruiting
Conditions
- Reducing Pain With Nexplanon Implant Insertion
Eligibility Criteria
- Sex
- FEMALE
- Age
- 14 Years - N/A
- Healthy Volunteers
- Accepted
Interventions
- Vapocoolant spray — DEVICEPain Ease will be used per manufacturer instruction, applying the spray for 5 seconds or until the skin turns white, whichever occurs first.
- Placebo — OTHERNature's Tears will be applied to the arm as a placebo spray
Study Details
The purpose of this study is to assess if Pain Ease vapocoolant spray decreases pain associated with lidocaine injection during Nexplanon insertion procedures.
Key Dates
- Start date
- Jun 16, 2025
- Status verified
- Jan 2026
- Primary completion
- Apr 1, 2026
- Completion
- May 1, 2026
Study Design
- Enrollment
- 70 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- SUPPORTIVE_CARE
Arms
- Experimental: Vapocoolant SprayThis is the study arm. Participants in this arm of the study will receive Pain Ease vapocoolant spray during their Nexplanon implant insertion in the arm. They will receive the spray on their arm right before lidocaine injection is administered for Nexplanon insertion procedure. Pain Ease vapocoolant spray is FDA approved for use on skin prior to common needle-stick procedures like intravenous (IV) starts and vaccines. The investigators will use the spray in a similar fashion, to help with the pain of lidocaine injection during Nexplanon insertion procedures. Physicians will do the Nexplanon procedure before any other procedures if patient has multiple procedures scheduled the same day.
- Placebo Comparator: Nature's TearsThis is the placebo. This group will receive Nature's Tears, which is a saline spray that does not offer analgesic effects.
Primary Outcome Measure
Pain with lidocaine injection [ Time Frame: Immediately after lidocaine injection ]
Central Contacts
- Sarah Murayama, MD808-783-0298
- Mary Tschann, PhD808-375-3785
Locations (3)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Queens Medical Center POB 2 Suite 402 | Honolulu | Hawaii | 96813 | Mary Tschann, PhD 808-375-3785 Sarah Murayama, MD (PRINCIPAL_INVESTIGATOR) Bliss Kaneshiro, MD MPH (PRINCIPAL_INVESTIGATOR) |
| Queens Medical Center POB1 Clinic 1004 | Honolulu | Hawaii | 96813 | Sarah Murayama, MD (PRINCIPAL_INVESTIGATOR) Bliss Kaneshiro, MD MPH (PRINCIPAL_INVESTIGATOR) |
| Women's Center Queen's North Hawai'i Community Hospital Suite #124 and #120 | Waimea | Hawaii | 96743 | Bliss Kaneshiro, MD, MPH (PRINCIPAL_INVESTIGATOR) |